1 – 20 of 25
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Mutant huntingtin interacts with {beta}-tubulin and disrupts vesicular transport and insulin secretion.
(
- Contribution to journal › Article
-
Mark
Beyond the brain: widespread pathology in Huntington's disease.
(
- Contribution to journal › Article
- 2008
-
Mark
Increased thirst and drinking in Huntington's disease and the R6/2 mouse
(
- Contribution to journal › Article
-
Mark
Increased metabolism in the R6/2 mouse model of Huntington's disease.
(
- Contribution to journal › Article
-
Mark
Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus
(
- Contribution to journal › Article
-
Mark
Islet beta-cell area and hormone expression are unaltered in Huntington's disease.
(
- Contribution to journal › Article
- 2007
-
Mark
Cocaine- and amphetamine-regulated transcript is increased in Huntington disease.
(
- Contribution to journal › Article
- 2006
-
Mark
Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease.
(
- Contribution to journal › Letter
-
Mark
Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease
(
- Contribution to journal › Article
- 2005
-
Mark
Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease.
(
- Contribution to journal › Article
-
Mark
Combining neuroprotective treatment of embryonic nigral donor tissue with mild hypothermia of the graft recipient.
(
- Contribution to journal › Article
-
Mark
Proteolysis of NR2B by calpain in the hippocampus of epileptic rats.
(
- Contribution to journal › Article
-
Mark
The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis.
(
- Contribution to journal › Article
-
Mark
Orexin loss in Huntington's disease.
(
- Contribution to journal › Article
- 2004
-
Mark
Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice
(
- Contribution to journal › Article
- 2002
-
Mark
Evidence for Dysfunction of the Nigrostriatal Pathway in the R6/1 Line of Transgenic Huntington's Disease Mice.
(
- Contribution to journal › Article
- 2001
-
Mark
Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration
(
- Contribution to journal › Article
-
Mark
Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine
(
- Contribution to journal › Article
-
Mark
Huntingtons sjukdom - ännu ett galet protein?
(
- Contribution to journal › Article
-
Mark
Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death
(
- Contribution to journal › Article